Radiopharm sets FDA meeting for RAD101 brain metastases trial design
Tweet Send to a Friend
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) has scheduled an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


